BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 25310918)

  • 1. A cost and resource utilization analysis of micafungin bridging for hemato-oncological high-risk patients undergoing allogeneic stem cell transplantation.
    Heimann SM; Vehreschild MJ; Cornely OA; Franke B; von Bergwelt-Baildon M; Wisplinghoff H; Kron F; Scheid C; Vehreschild JJ
    Eur J Haematol; 2015 Jun; 94(6):526-31. PubMed ID: 25310918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients.
    Vehreschild MJ; von Bergwelt-Baildon M; Tran L; Shimabukuro-Vornhagen A; Wisplinghoff H; Bangard C; Cornely OA; Vehreschild JJ
    Eur J Haematol; 2014 Nov; 93(5):400-6. PubMed ID: 24798021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and pharmacoeconomic evaluation of antifungal prophylaxis with continuous micafungin in patients undergoing allogeneic stem cell transplantation: A six-year cohort analysis.
    Wingen-Heimann SM; Cornely OA; Vehreschild MJGT; Wisplinghoff H; Franke B; Schons M; von Bergwelt-Baildon M; Scheid C; Vehreschild JJ
    Mycoses; 2021 Apr; 64(4):437-444. PubMed ID: 33354800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation.
    Schonfeld W; Wang Cheng J; Tong KB; Seifeldin R
    Clin Ther; 2008 May; 30(5):964-73. PubMed ID: 18555943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
    Sohn HS; Lee TJ; Kim J; Kim D
    Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Is micafungin useful in the prophylaxis of invasive fungal disease in hematological patients?].
    Salavert M; Jarque I
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():43-9. PubMed ID: 21420577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.
    Mehta PA; Vinks AA; Filipovich A; Bleesing J; Jodele S; Jordan MB; Marsh R; Tarin R; Edwards S; Fearing D; Lawrence J; Davies SM
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1458-62. PubMed ID: 20546908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
    Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
    Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK.
    Sidhu MK; van Engen AK; Kleintjens J; Schoeman O; Palazzo M
    Curr Med Res Opin; 2009 Aug; 25(8):2049-59. PubMed ID: 19575628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
    Ziakas PD; Kourbeti IS; Mylonakis E
    Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different doses of micafungin for prophylaxis of invasive fungal diseases in hemato-oncological high-risk patients: a web-based non-interventional trial in four large university hospitals in Germany.
    Heimann SM; Vehreschild MJ; Meintker L; Heinz W; Schroeder T; von Bergwelt-Baildon M; Cornely OA; Vehreschild JJ
    Transpl Infect Dis; 2014 Dec; 16(6):968-74. PubMed ID: 25371351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections.
    Masterton RG; Casamayor M; Musingarimi P; van Engen A; Zinck R; Odufowora-Sita O; Odeyemi IA
    J Med Econ; 2013 Nov; 16(11):1344-56. PubMed ID: 24003830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile Neutropenia.
    Fung M; Kim J; Marty FM; Schwarzinger M; Koo S
    PLoS One; 2015; 10(11):e0140930. PubMed ID: 26554923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Micafungin as antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: results of different dosage levels in clinical practice.
    Langebrake C; Rohde H; Lellek H; Wolschke C; Kröger NM
    Clin Transplant; 2014 Mar; 28(3):286-91. PubMed ID: 24479680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Efficacy and Safety of Caspofungin Versus Micafungin in Pediatric Allogeneic Stem Cell Transplant Recipients: A Retrospective Analysis.
    Maximova N; Schillani G; Simeone R; Maestro A; Zanon D
    Adv Ther; 2017 May; 34(5):1184-1199. PubMed ID: 28429246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifungal prophylaxis with micafungin in neutropenic patients with hematological malignancies.
    Hirata Y; Yokote T; Kobayashi K; Nakayama S; Oka S; Miyoshi T; Akioka T; Hiraoka N; Iwaki K; Takayama A; Nishimura Y; Makino J; Takubo T; Tsuji M; Hanafusa T
    Leuk Lymphoma; 2010 May; 51(5):853-9. PubMed ID: 20214445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: real-life data from a retrospective single-centre observational study.
    Nachbaur D; Angelova O; Orth-Höller D; Ditlbacher A; Lackner M; Auberger J; Lass-Flörl C
    Eur J Haematol; 2015 Mar; 94(3):258-64. PubMed ID: 25082655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
    Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment cost development of patients undergoing remission induction chemotherapy: a pharmacoeconomic analysis before and after introduction of posaconazole prophylaxis.
    Heimann SM; Cornely OA; Vehreschild MJ; Glossmann J; Kochanek M; Kreuzer KA; Hallek M; Vehreschild JJ
    Mycoses; 2014 Feb; 57(2):90-7. PubMed ID: 23790060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant.
    Huang X; Chen H; Han M; Zou P; Wu D; Lai Y; Huang H; Chen X; Liu T; Zhu H; Wang J; Hu J
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1509-16. PubMed ID: 22469884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.